Effect of alosetron on theophylline pharmacokinetics.
OBJECTIVE
To examine the potential for alosetron to alter the pharmacokinetics of theophylline by inhibiting its metabolism, as suggested by in vitro and in vivo effects on CYP1A2 activity.


METHODS
Ten healthy female volunteers received theophylline 200 mg twice daily alone for 8 days and with alosetron 1 mg twice daily for 15 days in this randomized, placebo-controlled, two-way-crossover study.


RESULTS
Alosetron had no significant effect on theophylline plasma concentrations (Cmax approximately 9 microg ml(-1), AUC approximately 90 microg ml(-1) h) or oral formation clearance of three major metabolites produced via CYP1A2: 3-methylxanthine, 1-methylurate and 1,3-dimethylurate (5, 7 and 16 ml min(-1), respectively). Concomitant administration of alosetron and theophylline was well tolerated.


CONCLUSIONS
The absence of a clinical drug interaction involving inhibition of theophylline metabolism by alosetron was not predicted by in vitro and in vivo metabolic probe data.
Koch
K M
KM
Glaxo Wellcome Inc., Research Triangle Park, North Carolina 27709, USA.
Ricci
B M
BM
Hedayetullah
N S
NS
Jewell
D
D
Kersey
K E
KE
D000293:Adolescent; D000328:Adult; D019540:Area Under Curve; D001993:Bronchodilator Agents / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*; D002243:Carbolines / Q000494:pharmacology*; D018592:Cross-Over Studies; D019388:Cytochrome P-450 CYP1A2 / Q000378:metabolism*; D004311:Double-Blind Method; D004347:Drug Interactions; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D012702:Serotonin Antagonists / Q000494:pharmacology*; D013806:Theophylline / Q000008:administration & dosage / Q000097:blood / Q000493:pharmacokinetics*
D001993:Bronchodilator Agents; D002243:Carbolines; D012702:Serotonin Antagonists; C090840:alosetron; D013806:Theophylline; D019388:Cytochrome P-450 CYP1A2